Karen A. Autio, Neeta Pandit-Taskar, Jorge A. Carrasquillo, Ryan D. Stephenson, Susan F. Slovin, Dana E. Rathkopf, Christina Hong, Glenn Heller, Howard I. Scher, Steven M. Larson and Michael J. Morris Repetitively dosed docetaxel and 153samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer Cancer 119
Combining bone-seeking radiopharmaceuticals with chemotherapy simultaneously targets the bone stroma and cancer cell to optimize treatment in patients with metastatic castration-resistant prostate cancer. Docetaxel and 153Sm-EDTMP (samarium-153 ethylene diamine tetramethylene phosphonate) were repetitively administered at US Food and Drug Administration-approved doses until disease progression/intolerance. The regimen was found to be well tolerated and effective, supporting combinations of tumor and bone-directed treatments.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf